Continuum Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$45.5K Buy
+73
New +$49.7K ﹤0.01% 812
2025
Q2
Sell
-2
Closed -$1.27K 1306
2025
Q1
$1.27K Sell
2
-4
-67% -$2.75K ﹤0.01% 1469
2024
Q4
$4.27K Sell
6
-5
-45% -$4.2K ﹤0.01% 1176
2024
Q3
$8.61K Buy
+11
New +$12.2K ﹤0.01% 1037

Other funds holding REGN

Continuum Advisory's REGN Position: Q2 2026 in Review

Continuum Advisory opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 73 shares worth $45.5K. The stake represents ﹤0.01% of the portfolio and ranks #812 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in REGN as recently as Q1 2025.

Continuum Advisory first reported a position in REGN in Q3 2024 and has held it in 4 quarters since. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Continuum Advisory held 73 shares of Regeneron Pharmaceuticals worth $45.5K as of Q2 2026.
  • Regeneron Pharmaceuticals was a new Continuum Advisory position in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #812 holding.
  • Continuum Advisory first reported a position in Regeneron Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.